Breaking News

Merck KGaA Appoints R&D Head

July 15, 2014

Rossetti brings extensive drug development experience

Luciano Rossetti, M.D., has been appointed executive vice president and global head of R&D at Merck KGaA’s biopharmaceutical division, as of July 21st. Dr. Rossetti will be based in Billerica, MA.
 
Dr. Rossetti most recently served as senior vice president of Late Stage Development at Merck Sharp & Dohme, where he was responsible for all clinical development from Phase II - V across all therapeutic areas. He also played a key role in implementing the development strategy of several potential breakthrough compounds such as anti PD-1.
 
“I’m thrilled to welcome Luciano Rossetti to our division,” said Belén Garijo, president and chief executive officer of the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. “His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world.”
blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer